GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

Overview

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Full Title of Study: “The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2011

Detailed Description

The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators. In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.

Arms, Groups and Cohorts

  • Sickle cell disease
  • hereditary spherocytosis.

Clinical Trial Outcome Measures

Primary Measures

  • GDF 15
    • Time Frame: year

Secondary Measures

  • Hepcidine
    • Time Frame: year

Participating in This Clinical Trial

Inclusion Criteria

  • non Exclusion Criteria:

  • non

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Wolfson Medical Center
  • Provider of Information About this Clinical Study
    • Dr’ Ghoti Hossam, hematology department on Wolfsson Medical Center
  • Overall Official(s)
    • GHOTI HOSSAM, doctor, Principal Investigator, HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER
  • Overall Contact(s)
    • Ghoti Hossam, doctor, 035028110, drghoti123@yahoo.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.